Since its inception in 1983, The John Douglas French Alzheimer's Foundation has raised over $20 million to fund ground-breaking Alzheimer's research.
Dorothy Kirsten French (a world famous soprano and opera diva) and her good friend, Richard K. Eamer (Founder, Chairman, and CEO of National Medical Enterprises—now Tenet Healthcare), founded the organization in August, 1983, in honor of Dorothy's husband, Dr. John Douglas French. Dr. French was a world renowned neurologist and Co-Founder and former Director of the UCLA Brain Research Institute. He died of Alzheimer's in 1989, after a career of searching for its cure.
Art Linkletter, TV host, author, and businessman served as Chairman of the Board for over 21 years. His active support of the Foundation during that time played a meaningful role in spreading awareness of the critical need for Alzheimer's research funding.
From the inception, Dr. Bruce Miller (Director of the UCSF Memory and Aging Center) has served as the Foundation's Chief Medical Officer.
Dr. Stanley Prusiner (Nobel Laureate) became the Chairman of the Foundation's International Scientific Advisory Board in 1996.
In 1998, Michael Minchin, Jr. became President and CEO of the Foundation, and in 2010, upon the death of Mr. Linkletter, Michael Reagan, son of President Ronald Reagan, was named the Foundation's Chairman. From 2016 - 2018, Dan Michel was the President of the Foundation when Mr. Minchin passed away. In 2018, Dr. Cheryl Mae Craft became President and CEO of the Foundation.
Karen Bedrosian Coyne, became President of The Founding Associates of The John Douglas French Alzheimer's Foundation in 2009. She leads this group of women in Southern California, whose primary mission is to raise money for AD research and to support the mission of The Foundation.
The John Douglas French Alzheimer's Foundation has raised over $20 million since 1983. Based on the recommendations of the Foundation's Board of Directors and the distinguished International Scientific Advisory Board, millions have been allocated to highly respected scientific research projects.